Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy

Study Overview
=================
Brief Summary
-----------------
The primary objective of the trial is to determine the effect of a 24-week concomitant coaching on patient reported outcomes of patients receiving standard treatment for mRCC with sunitinib or a combination of pembrolizumab + axitinib or avelumab + axitinib in first line therapy.

Detailed Description
-----------------
The goal of our study is to define the benefit of proactive coaching in mRCC, when compared to a reactive approach, which is considered the standard of care. Patients in the Coaching Arm A will be trained continuously at personal interactions of coach and patient (Face-to Face meetings as well as telephone contacts). The patient is educated on nature and severity of treatment emergent Adverse events (TEAE) of sunitinib or a combination of pembrolizumab + axitinib or avelumab + axitinib in first line therapy. Quality of Life (QoL) is assessed during sunitinib treatment in both arms (Arm A Coaching and Arm B non Coaching).

Official Title
-----------------
A Phase III Study Testing the Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic Renal Cell Carcinoma Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy

Conditions
-----------------
Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent

Intervention / Treatment
-----------------
* Behavioral: Concomitant coaching


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Written informed consent and any locally-required authorization (EU Data Privacy Directive in the EU) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations Age ≥ 18 years at time of study entry Advanced or metastatic renal cell carcinoma, not amendable to surgery with curative intent, rendering the patient eligible for Tyrosin Kinase Inhibitor (TKI) treatment with sunitinib Intended first-line treatment with sunitinib Documented progressive disease within 6 months prior to study inclusion Patients with measurable disease (at least one uni-dimensionally measurable target lesion by CT-scan or MRI) according to modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as well as non-measurable disease are eligible. Prior radiotherapy and surgery are allowed if completed 4 weeks (for minor surgery and palliative radiotherapy for bone pain: 2 weeks) prior to start of treatment and patient recovered from toxic effects. Female subjects must either be of non-reproductive potential (ie, post-menopausal by history: ≥60 years old and no menses for ≥1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry. Subject is willing to receive additional concomitant coaching and able to comply with the QoL/PRO (patient-reported outcome) assessments specified in the protocol for the duration of the study including scheduled visits, examinations and follow up. Exclusion Criteria: Any other anti-cancer treatment aside of sunitinib for mRCC (except palliative radiotherapy) Previous malignancy (other than mRCC) which either progresses or requires active treatment. Exceptions are: basal cell cancer of the skin, pre-invasive cancer of the cervix, T1a or T1b prostate carcinoma, or superficial bladder tumor [Ta, Tis and T1]. CNS metastases, unless local therapy has been completed for at least 3 month and patient does not require the use of steroids. Chronic liver disease with Child-Pugh B or C score Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control (failure rate of less than 1% per year) Any condition that, in the opinion of the investigator, would interfere with evaluation of the concomitant coaching or QoL assessments or interpretation of patient safety or study results Participation in another clinical study with an investigational product during the last 30 days before inclusion Any previous treatment with a tyrosine kinase inhibitor for metastatic disease. Adjuvant or neoadjuvant therapy for localized disease is permitted, provided that relapse occurred at least 6 months after last exposure Previous enrollment or randomization in the present study (does not include screening failure). Involvement in the planning and/or conduct of the study (applies to both Pfizer staff and/or staff of sponsor and study site) Patient who might be affiliated or otherwise dependent on the sponsor, site or the investigator Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities [§ 40 Abs. 1 S. 3 Nr. 4 AMG]. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm A (Coaching)<br>Concomitant coaching (24 weeks) Pro-active TEAE (Treatment emergent adverse events) management Cancer therapy according to Standard of Care (SOC) QoL assessments/ primary endpoint FKSI-15 | Behavioral: Concomitant coaching<br>* The corner stones of the pro-active coaching are as follows: Patient education: Information on nature and severity of treatment emergent AEs information about remedies for TEAEs propagation and explanation of tests and treatment decisions Patient instruction on self-care and preventive measures Preemptive AE treatment strategies Supervision of reported ADR severity, ADR mitigation strategies according to recommendations of the PREPARE protocol and cancer treatment modification by treating physician in close collaboration with the coach<br>|
| No Intervention: Arm B (Control)<br>Re-activeTEAE management (SOC) Cancer therapy according to Standard of Care (SOC) QoL assessments/ primary endpoint FKSI-15 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| QoL assessment during sunitinib treatment: questionnaire | Rate of responders to concomitant coaching assessed by the (Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)) FKSI-15 questionnaire. | 24 weeks from randomization | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective Response Rate (ORR) according to RECIST 1.1 criteria | Objective Response Rate (ORR) according to RECIST 1.1 criteria | up to one year from randomization | 
| Overall Survival (OS) | Overall Survival (OS) | up to 36 months from randomization | 
| progression-free survival (PFS) | progression-free survival (PFS) | up to 36 months from randomization | 
| Duration of treatment (coaching and cancer treatment) | Duration of treatment (coaching and cancer treatment) | Coaching: up to 24 weeks from randomization / cancer treatment: up to 36 months from randomization | 
| dose density of sunitinib | dose density of sunitinib | 24 weeks from randomization | 
| Rate of patients receiving treatment beyond progression | Rate of patients receiving treatment beyond progression | up to 36 months from randomization | 
| Further cancer treatment | Further cancer treatment | up to 36 months | 
| Time to first subsequent therapy (TFST) | Time to first subsequent therapy (TFST) | up to 36 months | 
| Patient adherence / treatment discontinuation due to Adverse drug reactions (ADRs) / Serious adverse events (SAEs): | % of patients with treatment discontinuation due to specific ADRs (e.g. hand-foot syndrome, diarrhea, stomatitis, fatigue, hypertension) | 24 weeks from randomization | 
| Treatment Emergent Adverse Events according to CTC 4.03: | Frequency/incidence, severity, percentage reduction, time-to-event of ADRs, AEs and specific TEAEs (e.g. hand-foot syndrome, diarrhea, stomatitis, fatigue, hypertension) change of grade 3/4 ADRs | 24 weeks from randomization | 
| Assessment of comorbidities | Charlson Comorbidity Index (CCI) | at inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Therapy-Coaching, Quality of Life